Sign up for the biotech newsletter to stay updated on the latest science and politics in the industry. Merck has cut the price of its diabetes drug Januvia, citing reasons related to patient benefits and changes in the Medicaid rebate program. Neumora’s experimental depression drug failed in a Phase 3 study, causing a significant drop in the company’s stock. There is a suggestion to split the FDA into two entities for better regulation and public trust. Roche is expanding its presence in the ADC space through collaborations with companies like Innovent. Other news includes Lilly joining a lawsuit and Pfizer canceling a hemophilia gene therapy deal.
Source link
Readout Newsletter: Neumora, Merck, Roche news
